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Reply to the Editor: 
My colleagues and I are pleased with the endorsement 
of the video-assisted thoracoscopic (VAT) technique for 
thymectomy by Mineo, Pompeo, and Ambrogi. It is 
heartening to see preliminary confirmation of the safety 
and efficacy of the technique in another institution. 
Regarding the issues raised in their letter, we also began 
the VAT approach for thymectomy from the left side 
because preoperative computed tomographic assessment 
indicated that the thymus gland was usually more promi- 
nent and larger on the left side. As a result of the 
experience of one of our colleagues (Anthony Yim), we 
gradually adopted the right-sided approach. Although it is 
a matter of surgical preference, we routinely have found 
the right-sided approach technically easier than the left- 
sided approach for a number of reasons. 
1. From the left side, the recess medial to the superior 
vena cava and inferior to the innominate vein was the 
most difficult area to visualize and dissect. This portion of 
the procedure is more easily accomplished from the right 
side. 
2. Identification of the innominate vein from the left 
side occasionally presented some difficulties. Initial iden- 
tification of the superior vena cava from the right side 
allows easy identification of and dissection along the 
innominate vein from the right side. 
3. For right-handed surgeons, performing a VAT oper- 
ation beginning inferiorly and working cephalad is ergo- 
nomically simpler from the right side of the patient han 
from the left side. 
4. A neck dissection is equally easy to accomplish from 
either side. 
In the final analysis, however, we believe that the 
surgeon's preference should rule--whichever side he or 
she feels most comfortable on is the one that should be 
used. Although we rarely use carbon dioxide insuffiation 
for most VAT procedures, we do think that VAT thymec- 
tomy is an instance in which the adjuvant pneumomedi- 
astinum facilitates visualization and dissection, especially 
when crossing to the opposite side and performing the 
dissection in the aortopulmonary window. It also facili- 
tates identification and dissection of the superior horns of 
the gland in the cervical area. As mentioned in the 
manuscript and by Mineo, Pompeo, and Ambrogi, we 
totally agree that removal of all anterior mediastinal tissue 
is necessary to assure a complete thymectomy. 
We congratulate Mineo, Pompeo, and Ambrogi on 
their experience with 12 cases. We believe that the 
technique, whether performed by the right- or left-sided 
approach, needs to be evaluated by longer follow-up in 
larger series first. We further believe that a multiinstitu- 
tional study to determine which side is more appropriate 
is a lesser issue that should be studied after efficacy of the 
procedure has been definitively proved by long-term fol- 
low-up. In the 14 months ince completion of our reported 
study, our results, although still intermediate, continue the 
early trends. 
Michael Mack, AID 
Cardiothothoracic Surgery Associates of North Texas PA 
Medical City Dallas Hospital 
7777 Forest Lane 
Suite 323-A 
Dallas, TX 75230 
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Treatment of heparin-induced thrombocytopenia 
To the Editor." 
In the November 1996 issue of the Journal (1996;112: 
1390-92), Ganjoo, Harloff, and Johnson reported the case 
of a patient with heparin-induced thrombocytopenia 
(HIT) treated by enoxaparin. They concluded that cardiac 
operations can be safely done with the use of a circuit 
coated with Carmeda Bioactive Surface (Medtronic, Ana- 
heim, Calif.) in combination with low-molecular-weight 
heparin in patients with HIT. I would like to comment on 
this conclusion. 
If thrombocytopenia develops as a result of heparin, the 
heparin infusion should be stopped immediately. It is, 
however, difficult to choose an alternative anticoagulant. 
Initial reports have described the use of low-molecular- 
weight heparin instead of unfractionated heparin. 1 Re- 
cently Warkentin, 2 Peters, 3Magnani. 4and their associates 
emphasized that low-molecular-weight heparin is not in- 
dicated for the treatment of patients with HIT because of 
extensive cross-reactivity (80% to 90%). Patients with 
HIT who were treated by the heparinoid danaparoid 
sodium (ORG 10172; Orgaran) had lower cross-reactivity 
(10%). However, before the heparin0id anaparoid so- 
dium (ORG 10172) or eventually low-molecular-weight 
heparin is substituted for heparin, the plasma of the 
patients hould be tested for cross-reactivity oward one 
or more of these agents (platelet aggregation or 14- 
seratonin release test). The alternative anticoagulant is 
safer if no cross-reactivity has been detected. If acute 
replacement of heparin is necessary, the best option is 
danaparoid sodium (ORG 10172). Other approaches to 
the treatment are not conclusive. 
F. P. J. Peters, MD 
University Hospital Maastricht 
Department of Internal Medicine 
Division of Haematology and Oncology 
Postbus 5800 
6202 AZ Maastricht, The Netherlands 
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Angiographic and electronlbeam computed 
tomography studies of retrograde cardioplegia via 
the coronary sinus 
To the Editor: 
We read with great interest he article "Angiographic 
and Electron-Beam Computed Tomography Studies of 
Retrograde Cardioplegia via the Coronary Sinus" au- 
thored by Farge and associates) Since 1993 our labora- 
tory has been addressing the distribution of cardioplegie 
solution delivered via the coronary sinus using explanted 
human hearts. Many of the authors' findings are similar to 
our previously published results; however, there are sig- 
nificant differences that we believe are worthy of discus- 
sion. 
Using their experimental technique, the authors could 
not demonstrate flow to the right ventricular free wall, 
regardless of whether the experimental contrast solution 
was delivered with the coronary sinus occluded at its 
ostium or not. In our article, "Gross and Microvaseular 
Distribution of Retrograde Cardioplegia in Explanted 
Human Hearts, ''2 we found clear anatomic gross and 
mierovaseular histologic evidence for right ventricular f ee 
wall perfusion when cardioplegic solution was delivered 
with the coronary sinus occluded (Fig. 1). In that study we 
used an inert intracapillary marker (NTB-2) to qualita- 
tively examine retrograde distribution. In another manu- 
script, "Coronary Sinus Ostial Occlusion During Retro- 
grade Delivery of Cardioplegic Solution Significantly 
Improves Cardioplegic Distribution and Efficacy, ''3 we 
also found clear evidence of capillary perfusion of right 
ventricular free wall myocardinm. In this experiment 
colored microspheres were added to cardioplegic solution, 
which was delivered retrogradely with the coronary sinus 
either open or occluded, to quantitatively determine 
regional microvascular flow. Right ventricular flow, as well 
as posterior intraventricular septal flow, was greatly aug- 
mented as a result of coronary sinus occlusion. Even 
without occlusion, however, right ventricular flow was 
documented. 
We believe these differing experimental conclusions are 
likely the result of differing experimental models. Flow 
through the coronary venous system and subsequent 
capillary or thebesian systems is governed by the resis- 
tance of the vascular beds and the viscosity of the fluid 
delivered. In our model, explanted human hearts are 
arrested by cold cardioplegia, excised and transferred to 
the laboratory, and subjected to experimental cardioplegic 
solutions within 20 minutes. We believe this model prop- 
erly mimics the clinical situation, and normal operative 
coronary venous vascular resistance is anticipated. The 
authors use cadaveric hearts for experimentation, but they 
do not state how these are obtained and preserved and 
Fig. 1. Transverse section of an explanted human heart 
near the apex after coronary sinus perfusion of the inert 
intravascular marker NTB-2. Note that the material is 
seen in the vasculature of both the left and right ventricles. 
within what time frame they are xamined. Such condi- 
tions, particularly if ischemia is involved, can greatly alter 
vascular resistance. In our microsphere studies, the micro- 
spheres are delivered within human blood cardioplegic 
solution. In our anatomic NTB-2 studies, the experimental 
solution was prepared so that its pH, viscosity, and 
osmolality all resembled blood cardioplegic solution. 
These properties of the authors' experimental solution are 
not mentioned within the article. Such variables, particu- 
larly viscosity, can significantly affect flow. We have found 
that to maintain a coronary sinus pressure of 30 to 40 mm 
Hg, with the coronary sinus occluded, blood cardioplegic 
solution needs to be delivered at a rate of approximately 
0.5 ml/gm of heart tissue per minute. The authors' finding 
of a coronary sinus pressure of 40 mm Hg with a flow rate 
of 100 ml/min suggests either an unusually high vascular 
resistance or very small experimental hearts. Finally, when 
one considers the relative mass differences between the 
left and right ventricles, is it possible that some right 
ventricular perfusion is occurring during these experi- 
ments but that its identification is below the sensitivity of 
electron-beam computed tomography? 
Despite our disagreement regarding right ventricular 
perfusion, this article contains two pieces of anatomic 
information that we have also found to be true. The first 
is the highly variable number of venovenous anastomo- 
ses between veins arising from the coronary sinus (most 
notably, the left anterior descending vein) and the 
posterior descending vein. We believe the quantity and 
quality of these anastomoses determine the amount of 
cardioplegic solution delivered to the posterior intra- 
ventricular septum and right ventricle when a transa- 
trial coronary sinus cannula is being used, whether it is 
